Related Experiment Video
Updated: Dec 19, 2025

Isolation and Expansion of Mesenchymal Stem/Stromal Cells Derived from Human Placenta Tissue
Published on: June 6, 2016
GMP-Compliant Production of Human Placenta-Derived Mesenchymal Stem Cells
Hamid Reza Aghayan1, Moloud Payab2, Fereshteh Mohamadi-Jahani3
1Cell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Abstract:
Mesenchymal stem cells are one of the most attractive sources for stem cell research and therapy. Their safety and efficacy have been demonstrated in many clinical trials. Because of their low immunogenicity and immunomodulatory properties, allogenic MSCs have been transplanted in different clinical studies. MSCs could be in different adult- and fetal-derived tissues including pregnancy products. Placenta-derived mesenchymal stem cells (PLMSCs) that can be harvested without using any invasive procedures from a discarding tissue are one of the important types of mesenchymal stem cells for therapeutic applications. Stem cell manufacturing for therapeutic applications should be in compliance with the basic principles of good manufacturing practice (GMP). Herein, the current chapter is to describe GMP-compliant production of human PLMSCs, which are suitable for clinical applications.

